UCB achieved positive results from the Phase III active-controlled BE SURE study comparing the investigational IL-17A and IL-17F inhibitor bimekizumab to the TNF inhibitor adalimumab (Abbvie’s Humira) in the treatment of moderate-to-severe plaque psoriasis. The trial met its co-primary endpoints at week 16, demonstrating superiority of bimekizumab to adalimumab in achieving at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) and Investigator Global Assessment (IG...